Table 1.

Examples of liquid-based biopsy studies to detect ovarian cancer using ctDNA and CTCs.

Platform usedSelection parametersCase sizeControl sizeSensitivityaSpecificityaCI (95%)References
CTCsCellSearch®EpCAMHistologic diagnosis of ovarian cancern = 29n = 17a Benign disease25.7%100%Se = 12.5% ± 43.3% Sp = 76.8% ± 100%43
Cancer with metastases to the ovaryn = 5
Circulating tumor DNA (ctDNA)Microarray (MethDet 56)Promoters: RASSF1A, CALCA, EP300Benign diseasen = 30n = 3090%86.7%Se = 80% ± 100% Sp = 66.7% ± 96.7%75
Ovarian cancern = 30
Microfluidic digital PCRTP53-mutant allele fractionOvariann = 32n = 571%88%Se = 42% ± 92% Sp = 64% ± 99%71
Primary peritonealn = 5
Fallopian tuben = 3
Ultra-high coverage bi-sulfite sequencingUnspecified 3 DNAme marker panelOvarian cancern = 41n = 2141.4%90.7%Se = 24.1% ± 60.9% Sp = 84.3% ± 94.8%76
Other cancern = 37
Nonepithelial tumorsn = 5
Borderlinen = 27
Benign tumorsn = 119
  • Note: Pairs of sensitivity and specificity in this table are not directly comparable with each other because they are calculated on the basis of different cutoffs throughout.

  • aSensitivity (Se) and specificity (Sp) pair values listed correspond to a specific decision cutoff utilized in each study.